High-Grade Pleomorphic Sarcomas Treated with Immune Checkpoint Blockade: The MD Anderson Cancer Center Experience

Authors

Lewis F Nasr
Marianne Zoghbi
Rossana Lazcano
Michael Nakazawa
Andrew J Bishop
Ahsan Farooqi
Devarati Mitra
Beverly Ashleigh Guadagnolo
Robert Benjamin
Shreyaskumar Patel
Vinod Ravi
Dejka M Araujo
Andrew Livingston
Maria A Zarzour
Anthony P Conley
Ravin Ratan
Neeta Somaiah
Alexander J Lazar
Christina Roland
Emily Z Keung
Elise F Nassif Haddad

Publication Date

5-1-2024

Journal

Cancers

Abstract

BACKGROUND: Undifferentiated pleomorphic sarcomas (UPSs) are amongst the most common subtypes of soft-tissue sarcomas. Few real-world data on the use of immune checkpoint blockade (ICB) in UPS patients and other high-grade pleomorphic STS patients are available.

PURPOSE: The purpose of our study is to describe the efficacy and toxicity of ICB in patients with advanced UPSs and other high-grade pleomorphic sarcomas treated at our institution.

METHODS: This is a retrospective, observational study of all patients with metastatic high-grade pleomorphic sarcomas treated with FDA-approved ICB at MD Anderson Cancer Center between 1 January 2015 and 1 January 2023. Patients included in trials for which results are not yet published were excluded.

RESULTS: Thirty-six patients with advanced/metastatic pleomorphic sarcomas were included. The median age was 52 years. A total of 26 patients (72%) had UPSs and 10 patients (28%) had other high-grade pleomorphic sarcomas. The median follow-up time was 8.8 months. The median PFS was 2.9 months. The 3-month PFS and 6-month PFS were 46% and 32%, respectively. The median OS was 12.9 months. The 12-month OS and 24-month OS were 53% and 29%, respectively. The best response, previous RT, and type of ICB treatment were significantly and independently associated with shorter PFS (

CONCLUSIONS: Real-world retrospective data are consistent with the published literature, with a promising 6-month PFS of 32%. Partial or stable responders to ICB treatment have significantly improved PFS compared to progressors.

Keywords

immunotherapy, anti-PD1, real world, sarcoma, undifferentiated pleomorphic sarcomas, survival, clinical

Comments

Supplementary Material

Data Availability Statement

PMID: 38730715

DOI

10.3390/cancers16091763

PMID

38730715

PMCID

PMC11083765

PubMedCentral® Posted Date

May 2024

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes